Login to Your Account

TLC Adds New Asian Partner in Sciclone PAD Collaboration

By Dave Silver
Staff Writer

Friday, June 28, 2013

TAIPEI, Taiwan – Drug reformulation specialist Taiwan Liposome Co. (TLC), of Taipei, Taiwan, said it granted Sciclone Pharmaceuticals Inc., of Foster City, Calif., exclusive rights to distribute Proflow, its treatment for peripheral arterial disease (PAD), in China, Macau and Hong Kong.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription